Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.
Actively Recruiting
Researchers are evaluating whether apixaban, an oral anticoagulant tablet, can reduce blood clots in people with lung cancer who are receiving chemotherapy or similar systemic anticancer treatments. Venous thromboembolism VTE is a common and serious complication in lung cancer patients undergoing such therapies, leading to poorer quality of life, higher healthcare costs, and increased morbidity and mortality. Current standard care does not routinely use blood thinners for outpatients receiving systemic anticancer therapy, and this trial aims to address that gap. Participants will be randomly assigned to receive either apixaban 2.5 mg tablets or a matching placebo, taken twice daily by mouth for six months alongside their cancer treatments. This phase 3, multicenter, double-blind, placebo-controlled trial will compare these two groups to assess if apixaban reduces the rate of VTE. The trial includes a total of 1456 patients recruited over 36 months with a follow-up period of 6 months for primary outcome measurement. During the trial, participants will be asked to take the study medication as directed and complete diaries recording treatment adherence. They will also complete quality of life and health resource use questionnaires. Researchers will monitor for blood clots confirmed by objective testing, bleeding events, survival outcomes, and patient-reported quality of life over six months. Female participants who can become pregnant are required to use effective contraception during and shortly after treatment. The studys total duration, including setup and analysis, is planned for 60 months.
Actively Recruiting
This research is investigating the use of Implantable Cardioverter-Defibrillators ICDs in adults diagnosed with heart failure caused by Non-Ischemic Cardiomyopathy NICM, a condition where heart failure is not due to blocked arteries. The study aims to compare the all-cause mortality rates between patients who receive an ICD and those who do not, over a period of 36 months and extending up to 10 years. This trial addresses ongoing questions about whether ICDs benefit patients with NICM, especially given recent findings that many patients with ICDs do not experience serious heart rhythm problems. Participants are randomly assigned to one of two groups one group will have an ICD or Cardiac Resynchronisation Therapy Defibrillator CRTD implanted, which are devices designed to detect and correct dangerous heart rhythms. The other group will not receive an ICD but may have an Implantable Loop Recorder or a Cardiac Resynchronisation Therapy Pacemaker CRTP, alongside their usual medical care. The study will monitor both groups to determine if ICD implantation improves survival compared to no ICD over the study period. Throughout the trial, participants will be regularly evaluated with health assessments including quality of life questionnaires and monitoring of heart-related events such as hospitalizations and arrhythmias. Researchers will track outcomes like survival percentage, heart rhythm events, and device-related procedures over 3 years, with some outcomes also measured at 5 and 10 years. The study includes close observation of safety and effectiveness, with participants followed to understand long-term impacts of ICD therapy in this patient group.